Studies on ovarian cancer cell lines have also shown that the MMR pathway’s inactivation can reduce the sensitivity to cisplatin and carboplatin, yet has no significant effect on oxaliplatin (55). The gene discussed is MRC1; the disease is ovarian cancer.